Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Mitsubishi UFJ Asset Management UK Ltd.

Mitsubishi UFJ Asset Management UK Ltd. grew its position in Illumina, Inc. (NASDAQ:ILMN) by 116.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,000 shares of the life sciences company’s stock after purchasing an additional 7,000 shares during the period. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in Illumina were worth $1,737,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Versant Capital Management Inc boosted its position in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the period. TD Private Client Wealth LLC raised its stake in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares in the last quarter. Private Trust Co. NA raised its stake in shares of Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after buying an additional 212 shares in the last quarter. Finally, Focused Wealth Management Inc bought a new stake in shares of Illumina in the 3rd quarter worth $63,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $141.31 on Wednesday. The business has a 50 day moving average price of $139.30 and a 200 day moving average price of $133.99. Illumina, Inc. has a twelve month low of $100.08 and a twelve month high of $156.66. The company has a market cap of $22.41 billion, a price-to-earnings ratio of -14.19 and a beta of 1.11. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.33 EPS. Research analysts predict that Illumina, Inc. will post 4.13 earnings per share for the current year.

Analyst Ratings Changes

ILMN has been the topic of a number of recent analyst reports. Royal Bank of Canada boosted their target price on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Piper Sandler cut their target price on Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Barclays boosted their target price on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and cut their target price for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, TD Cowen boosted their target price on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $165.63.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.